Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 378 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Dog Showers His Mom with Snuggles and Makes Her Laugh During... December 6, 2021 Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... March 18, 2025 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... March 21, 2025 We want every scientist to thrive in cancer research July 28, 2023 Load more HOT NEWS A New Online Tool Predicts RFS and OS Probabilities in Patients... Company Gives Cancer Patient a New HVAC System After Treatment and... ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and... Opinion: ‘Medical research charities are falling through the cracks of COVID-19...
